A randomised, open label, parallel group, multi-centre, phase II study of progression free survival comparing ZD1839 (IRESSA) (250 mg tablet) versus vinorelbine (30 mg/mexp2) infusion in chemonaive, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC [non-small cell lung cancer]

Trial Profile

A randomised, open label, parallel group, multi-centre, phase II study of progression free survival comparing ZD1839 (IRESSA) (250 mg tablet) versus vinorelbine (30 mg/mexp2) infusion in chemonaive, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC [non-small cell lung cancer]

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2008

At a glance

  • Drugs Gefitinib; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms INVITE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Sep 2008 Primary endpoint 'Progression free survival' has not been met.
    • 10 Sep 2008 Results reported in the Journal of Clinical Oncology.
    • 17 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top